Reduction in the Evolution of Murine Type II Collagen-Induced Arthritis by Treatment with Rosiglitazone, a Ligand of the Peroxisome Proliferator-Activated Receptor γ

Arthritis and Rheumatism

Volumn 48, Issue 12, 2003, Pages 3544-3556

  Cuzzocrea, Salvatore ^a,d   Mazzon, Emanuela ^a   Dugo, Laura ^a   Patel, Nimesh S A ^b   Serraino, Ivana ^a   Di Paola, Rosanna ^a   Genovese, Tiziana ^a   Britti, Domenico ^c   De Maio, Massimo ^a   Caputi, Achille P ^a   Thiemermann, Christoph ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF TERAMO   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CELL NUCLEUS RECEPTOR; COLLAGEN TYPE 2; CYTOKINE; FREUND ADJUVANT; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID; ROSIGLITAZONE; STEROID; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; ERYTHEMA; GENE TARGETING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOLYSIS; PAW EDEMA; PRIORITY JOURNAL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; CYCLOOXYGENASE 2; INTERLEUKIN-1; INTERLEUKIN-6; ISOENZYMES; JOINTS; LIPID PEROXIDATION; MICE; MICE, INBRED DBA; NEUTROPHILS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLY(ADP-RIBOSE) POLYMERASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VASODILATOR AGENTS;

EID: 10744224449     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11351     Document Type: Article

References (83)

1. Harris ED Jr, Rheumatoid arthritis: pathophysiology and implications for therapy [published erratum appears in N Engl J Med 1990;323:996]. N Engl J Med 1990;322:1277-89.
2. Harris ED Jr, Rheumatoid arthritis: pathophysiology and implications for therapy [published erratum appears in N Engl J Med 1990;323:996]. N Engl J Med 1990;322:1277-89.
3. Stuart JM, Townes AS, Kang AH. Collagen autoimmune arthritis. Annu Rev Immunol 1984;2:199-218.
4. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol Rev 1990;118:193-232.
5. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K. The neutrophil activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989;243:1464-6.
6. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990;347:669-71.
7. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 1993;361:79-82.
8. Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-1β. Science 1993;260:355-8.
9. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
10. Ricote M, Huang JT, Welch JS, Glass CK. The peroxisome proliferator-activated receptor (PPAR-γ) as a regulator of monocyte/macrophage function. J Leukocyte Biol 1999;66:733-9.
11. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000;448: 121-38.
12. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol 2000;40:491-518.
13. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999;354:141-8.
14. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106:1305-7.
15. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803-12.
16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995;270:12953-6.
17. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, et al. Thiazolidinediones produce a conformational change in peroxisome proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-95.
18. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-8.
19. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997;272:3406-10.
20. Verrando P, Negrel R, Grimaldi P, Murphy M, Ailhaud G. Differentiation of ob 17 preadipocytes to adipocytes: triggering effects of clofenapate and indomethacin. Biochim Biophys Acta 1981;663:255-65.
21. Knight DM, Chapman AB, Navre M, Drinkwater L, Bruno JJ, Ringold GM. Requirements for triggering of adipocyte differentiation by glucocorticoids and indomethacin. Mol Endocrinol 1987;1:36-43.
22. Jiang C, Ting A, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
23. Ricote M, Li AC, Willson TM, Kelly J, Glass CK. The peroxisome proliferator activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
24. Campbell IK, Hamilton JA, Wicks IP. Collagen-induced arthritis in C57BL/ 6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 2000;30:1568-75.
25. Szabó C, Virag L, Cuzzocrea S, Scott GS, Hake P, O'Connor M, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthetase. Proc Natl Acad Sci U S A 1998;9;3867-72.
26. Cuzzocrea S, Zingarelli B, Costantino G, Caputi AP. Beneficial effects of Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic, in carrageenan-induced pleurisy. Free Rad Biol Med 1999;26;25-33.
27. Cuzzocrea S, Misko TP, Costantino G, Mazzon E, Micali A, Caputi AP, et al. Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. FASEB J 2000;14:1061-72.
28. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95; 351-8.
29. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39: 495-503.
30. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunke SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-69.
31. Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985;59:1978-85.
32. Youn YK, Lalonde C, Demling R. Use of antioxidant therapy in shock and trauma. Circ Shock 1991;35:245-9.
33. Cuzzocrea S, McDonald MC, Mazzon E, Siriwardena D, Calabro G, Britti D, et al. The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation. Am J Pathol 2000;157:145-58.
34. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001;53:135-59.
35. Holmdahl R, Mo J, Nordling C, Larsson P, Jansson L, Goldschmidt T, et al. Collagen induced arthritis: an experimental model for rheumatoid arthritis with involvement of both DTH and immune complex mediated mechanisms. Clin Exp Rheumatol 1989;7 Suppl 3:S51-5.
36. Hom JT, Bendele AM, Carlson DG. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J Immunol 1988;141:834-41.
37. Hom JT, Gliszczynski VL, Cole HW, Bendele AM. Interleukin 1 mediated acceleration of type II collagen-induced arthritis: effects of anti-inflammatory or anti-arthritic drugs. Agents Actions 1991; 33:300-9.
38. Hom JT, Cole H, Estridge T, Gliszczynski VL. Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice. Clin Immunol Immunopathol 1992;62:56-65.
39. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
40. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen induced arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77:510-4.
41. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor a and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992;89:7375-9.
42. Takai Y, Seki N, Senoh H, Yokota T, Lee F, Hamaoka T, et al. Enhanced production of interleukin-6 in mice with type II collagen-induced arthritis. Arthritis Rheum 1989;32:594-600.
43. Cooper SM, Sriram S, Ranges GE. Suppression of murine collagen-induced arthritis with monoclonal ant-Ia antibodies and augmentation with IFN-γ. J Immunol 1988;141:1958-62.
44. Mauritz NJ, Holmdahl R, Jonsson R, Van der Meide PH, Scheynius A, Klareskog L. Treatment with γ-interferon triggers the onset of collagen arthritis in mice. Arthritis Rheum 1988;31: 1297-304.
45. Brennan FM, Zachariae COC, Chantry D, Larsen CG, Turner M, Maini RN, et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin-8 mRNA by isolated synovial cells. Eur J Immunol 1990;20:2141-4.
46. Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991;147:2187-95.
47. Seitz M, Dewald B, Gerber N, Baggiolini M. Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin Invest 1991;87:463-9.
48. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992;149:722-7.
49. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.
50. Rathanaswami P, Hachicha M, Sadick M, Schall TJ, McColl SR. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts: differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993;268: 5834-9.
51. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. Macrophage inflammatory protein-1α: a novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994;93:921-8.
52. Welgus HG, Jeffrey JJ, Eisen AZ. The collagen substrate specificity of human skin fibroblast collagenase. J Biol Chem 1981;256: 9511-5.
53. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 1991;34:1094-105.
54. Sabatini M, Bardiot A, Lesur C, Moulharat N, Thomas M, Richard I, et al. Effects of agonists of peroxisome proliferator-activated receptor γ on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage 2002;10:673-9.
55. Bordji K, Grillasca JP, Gouze JN, Magdalou J, Schohn H, Keller JM, et al. Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage: PPARγ activation modulates the effects of interleukin-1β on rat chondrocytes. J Biol Chem 2000;275:12243-50.
56. Fahmi H, Di Battista JA, Pelletier J-P, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-1β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001;44:595-607.
57. Fahmi H, Pelletier J-P, Di Battista JA, Cheung HS, Fernandes JC, Martel-Pelletier J. Peroxisome proliferator-activated receptor γ activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1. Osteoarthritis Cartilage 2002;10:100-8.
58. Chatham WW, Swaim R, Frohsin H Jr, Heck LW, Miller EJ, Blackburn WD Jr. Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum 1993;36:51-8.
59. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al. Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995;4:281-99.
60. Murao K, Imachi H, Momoi A, Sayo Y, Hosokawa H, Sato M, et al. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999;454:27-30.
61. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000;164:6503-8.
62. Eiserich JP, Cross CE, Jones AD, Halliwell B, van der Vliet A. Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid: a novel mechanism for nitric oxide-mediated protein modification. J Biol Chem 1996;271: 19199-208.
63. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998;391: 393-7.
64. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 1997; 411:157-60.
65. Cuzzocrea S, Zingarelli B, Hake P, Salzman AL, Szabó C. Anti-inflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. Free Radic Biol Med 1998;24:450-9.
66. Cuzzocrea S, Costantino G, Mazzon E, Caputi AP. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy. Br J Pharmacol 1999;126:407-14.
67. Salvemini D, Wang ZQ, Stern MK, Currie MG, Misko TP. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc Natl Acad Sci U S A 1998;95: 2659-63.
68. Ialenti A, Moncada S, Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide Br J Pharmacol 1993;110: 701-6.
69. Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice: characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol 1985;22:295-306.
70. Brahn E, Banquerigo ML, Firestein GS, Boyle DL, Salzman AL, Szabó C. Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. J Rheumatol 1998;25:1785-93.
71. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-4.
72. Szabó C, Lim LHK, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, et al. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J Exp Med 1997;186:1041-9.
73. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor κB (NF-κB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-63.
74. Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J Clin Invest 1997;100:2443-8.
75. Staels B, Koenig W, Habib A. Activation of human aortic smooth-muscle cells is inhibited by PPARγ but not by PPARγ activators. Nature 1998;393:790-3.
76. Kamei Y, Xu L, Heinzel T. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996;85:403-14.
77. Karin M. The NF-κB activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am 1998;4 Suppl 1:S92-9.
78. 2 attenuates the development of acute and chronic inflammation. Mol Pharmacol 2002;61:997-1007.
79. 2 in activated human astrocytes, but not in human brain macrophages. J Immunol 2002;168: 4747-55.
80. 2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int 2002;61: 1957-67.
81. Simonin MA, Bordji K, Boyault S, Bianchi A, Gouze E, Becuwe P, et al. PPAR-γ ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol Cell Physiol 2002;282:C125-33.
82. Kalajdzic T, Faour WH, He QW, Fahmi H, Martel-Pelletier J, Pelletier J-P, et al. Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Arthritis Rheum 2002;46:494-506.
83. Ikawa H, Kameda H, Kamitani H, Baek SJ, Nixon JB, Hsi LC, et al. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp Cell Res 2001;267:73-80.